Personalized treatment of RET-altered thyroid cancers

touchEXPERT OPINIONS for touchONCOLOGY

Listen to leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers

The experts

• Prof. Maria Cabanillas - University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Dr Vivek Subbiah - University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Dr Lori Wirth - Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA, USA
  
  

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from from Blueprint Medicines and Genentech, a member of the Roche Group. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/personalized-treatment-of-ret-altered-thyroid-cancers-what-is-the-value-of-biomarker-testing-and-targeted-therapies/?_ga=2.29473663.1151443503.1654521477-1202917360.1651662103